Press Coverage | July 29, 2026

Where Big Pharma Is Betting Big in the M&A Boom

RELATED PROFESSIONALS

Douglas G. Gray

Douglas G. Gray, a partner in Troutman Pepper Locke's Health Care + Life Sciences Department, was quoted in the July 29, 2026, *Life Sciences IP Review* article, "Where Big Pharma Is Betting Big in the M&A Boom."

> Rayski says demand for GLP-1 and metabolic disease programmes is "particularly strong", while Douglas Gray, partner at Troutman, describes the cardiometabolic and obesity space as "another highly competitive area", with Big Pharma racing to stake a position in a market with "high commercial potential".
>
> Rare diseases are also attracting growing attention. Gray says orphan drug exclusivity and premium pricing continue to make the area attractive, while Griebel says there is sustained interest in immunology and inflammation, neuroscience, rare diseases, and cell and gene therapies.
>
> Gray similarly points to AI-native biotech platforms as an emerging area for dealmaking.

RELATED INDUSTRIES + PRACTICES

- Health Care + Life Sciences